Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 10/2016

Open Access 01-10-2016 | Original Article

G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma

Authors: Xiao-Dong Huang, Feng-Jun Xiao, Shao-Xia Wang, Rong-Hua Yin, Can-Rong Lu, Qing-Fang Li, Na Liu, Ying zhang, Li-Sheng Wang, Pei-Yu Li

Published in: Tumor Biology | Issue 10/2016

Login to get access

Abstract

Liposarcoma(LPS) is the most common type of soft tissue sarcoma accounting for 20 % of all adult sarcomas. However, the molecular pathogenesis of this malignancy is still poorly understood. Here, we showed that GPS2 expression was downregulated in LPS and correlated with the prognosis of this disease. In vitro study showed that knockdown of GPS2 resulted in enhanced proliferation and migration of LPS cell line SW872, without significant influence of cell death. Conclusively, our results suggest that GPS2 may act as a tumor suppressor in LPS and serve as a potential prognosis marker for this disease.
Literature
1.
2.
Jo VY, Fletcher CD. WHO classification of soft tissue tumours: an update based on the 2013 (4th) edition. Pathology. 2014;46(2):95–104.CrossRefPubMed
3.
Rosai J et al. Combined morphologic and karyotypic study of 59 atypical lipomatous tumors. Evaluation of their relationship and differential diagnosis with other adipose tissue tumors (a report of the CHAMP study group). Am J Surg Pathol. 1996;20(10):1182–9.CrossRefPubMed
4.
5.
Dalal KM, Antonescu CR, Singer S. Diagnosis and management of lipomatous tumors. J Surg Oncol. 2008;97(4):298–313.CrossRefPubMed
6.
Zagars GK et al. Surgical margins and reresection in the management of patients with soft tissue sarcoma using conservative surgery and radiation therapy. Cancer. 2003;97(10):2544–53.CrossRefPubMed
7.
Taylor BS et al. Frequent alterations and epigenetic silencing of differentiation pathway genes in structurally rearranged liposarcomas. Cancer Discov. 2011;1(7):587–97.CrossRefPubMedPubMedCentral
8.
Crago AM et al. Copy number losses define subgroups of dedifferentiated liposarcoma with poor prognosis and genomic instability. Clin Cancer Res. 2012;18(5):1334–40.CrossRefPubMedPubMedCentral
9.
Ugras S et al. Small RNA sequencing and functional characterization reveals MicroRNA-143 tumor suppressor activity in liposarcoma. Cancer Res. 2011;71(17):5659–69.CrossRefPubMedPubMedCentral
10.
Zhang P et al. MiR-155 is a liposarcoma oncogene that targets casein kinase-1alpha and enhances beta-catenin signaling. Cancer Res. 2012;72(7):1751–62.CrossRefPubMedPubMedCentral
11.
12.
Cantile M et al. Hyperexpression of HOXC13, located in the 12q13 chromosomal region, in well-differentiated and dedifferentiated human liposarcomas. Oncol Rep. 2013;30(6):2579–86.PubMedPubMedCentral
13.
Peng T et al. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Investig. 2011;91(3):392–403.CrossRefPubMed
14.
Ray-Coquard I et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma an exploratory proof-of-mechanism study. Lancet Oncol. 2012;13(11):1133–40.CrossRefPubMed
15.
Spain BH et al. Two human cDNAs, including a homolog of Arabidopsis FUS6 (COP11), suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction in yeast and mammalian cells. Mol Cell Biol. 1996;16(12):6698–706.CrossRefPubMedPubMedCentral
16.
Cheng X, Kao HY. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation. J Biol Chem. 2009;284(52):36395–404.CrossRefPubMedPubMedCentral
17.
18.
Lee TH et al. Formation of hMSH4-hMSH5 heterocomplex is a prerequisite for subsequent GPS2 recruitment. DNA Repair (Amst). 2006;5(1):32–42.CrossRef
19.
Wu H et al. Coordinated regulation of AIB1 transcriptional activity by sumoylation and phosphorylation. J Biol Chem. 2006;281(31):21848–56.CrossRefPubMed
20.
Venteclef N et al. GPS2-dependent corepressor/SUMO pathways govern anti-inflammatory actions of LRH-1 and LXRbeta in the hepatic acute phase response. Genes Dev. 2010;24(4):381–95.CrossRefPubMedPubMedCentral
21.
O’Meara E et al. Identification of an MLL4-GPS2 fusion as an oncogenic driver of undifferentiated spindle cell sarcoma in a child. Genes Chromosom Cancer. 2014;53(12):991–8.CrossRefPubMed
22.
Toubal A et al. SMRT-GPS2 corepressor pathway dysregulation coincides with obesity-linked adipocyte inflammation. J Clin Invest. 2013;123(1):362–79.CrossRefPubMed
23.
24.
Wang Z et al. Targeting miRNAs involved in cancer stem cell and EMT regulation: an emerging concept in overcoming drug resistance. Drug Resist Updat. 2010;13(4–5):109–18.CrossRefPubMedPubMedCentral
25.
Rosen ED, Spiegelman BM. PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001;276(41):37731–4.CrossRefPubMed
26.
27.
28.
29.
30.
31.
Kunstlinger H et al. FGFR2 is overexpressed in myxoid liposarcoma and inhibition of FGFR signaling impairs tumor growth in vitro. Oncotarget. 2015;6(24):20215–30.CrossRefPubMedPubMedCentral
32.
Mariani O et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11(4):361–74.CrossRefPubMed
33.
Jin DY et al. A human suppressor of c-Jun N-terminal kinase 1 activation by tumor necrosis factor alpha. J Biol Chem. 1997;272(41):25816–23.CrossRefPubMed
34.
Jakobsson T et al. GPS2 is required for cholesterol efflux by triggering histone demethylation, LXR recruitment, and coregulator assembly at the ABCG1 locus. Mol Cell. 2009;34(4):510–8.CrossRefPubMed
Metadata
Title
G protein pathway suppressor 2 (GPS2) acts as a tumor suppressor in liposarcoma
Authors
Xiao-Dong Huang
Feng-Jun Xiao
Shao-Xia Wang
Rong-Hua Yin
Can-Rong Lu
Qing-Fang Li
Na Liu
Ying zhang
Li-Sheng Wang
Pei-Yu Li
Publication date
01-10-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 10/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5220-x

Other articles of this Issue 10/2016

Tumor Biology 10/2016 Go to the issue

Original Article

Investigation of N-cadherin/β-catenin expression in adrenocortical tumors

Original Article

Alternative splicing of S6K1 promotes non-small cell lung cancer survival

Original Article

The inflammatory microenvironment in epithelial ovarian cancer: a role for TLR4 and MyD88 and related proteins

Original Article

Tescalcin expression contributes to invasive and metastatic activity in colorectal cancer

Original Article

DNA repair pathways to regulate response to chemoradiotherapy in patients with locally advanced head and neck cancer

Original Article

Proteomic analysis of differentially expressed proteins in vitreous humor of patients with retinoblastoma using iTRAQ-coupled ESI-MS/MS approach

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits